Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

VVUS—This might be a good time to review

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 494
Posts 82,509
Boards Moderated 24
Alias Born 09/05/02
160x600 placeholder
Roche Hit By Failure Of Cancer Drug Trial
Roche said a late-stage study of its breast cancer drug Kadcyla failed to yield superior results to an existing treatment, damaging the outlook for stronger sales in one of its key drug markets.
More Top Equities Stories Of The Day
Deezer Names New CEO Before Full U.S. Launch
Whistleblowers Score a Big Payday -- Update
Mobile's Rise Poses a Riddle for Banks
AT&T Boosts Dividend
U.S. Hot Stocks: Hot Stocks to Watch
Brazilian Shares Rise, Led by Rossi Residencial; Real Weakens Slightly
Oracle Beats Street View for First Time in a Year
Alstom CEO Expects to Settle DOJ Bribery Allegations Very Soon
DewDiligence Member Level  Thursday, 02/23/12 11:29:54 AM
Re: biotech jim post# 137678
Post # of 184884 
VVUS—This might be a good time to review the table in #msg-59407483 :- )

Note that Contrave is one of the items on the list.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist